Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-16

FDA Approved: ABACAVIR AND LAMIVUDINE — Original Application (Camber Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves Camber Pharmaceuticals' Abacavir and Lamivudine as an original application for the treatment of HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABACAVIR AND LAMIVUDINE (abacavir/lamivudine)

Snippet

ORIG AP for ABACAVIR AND LAMIVUDINE (ABACAVIR AND LAMIVUDINE)